Precigen, Inc. (PGEN)
NASDAQ
Healthcare
Biotechnology
$7.23
▲ +4.63%
Market Cap
$2.58B
Sector
Healthcare
Industry
Biotechnology
Beta
1.00
52-Wk Range
1.7-7.26
CEO
Helen Sabzevari
Country
US
Currency
USD
Precigen, Inc. is an American company dedicated to the discovery and development of cutting-edge gene and cellular therapies. The company also offers disease-modifying treatments, genetically engineered swine for regenerative medicine, and advanced reproductive and embryo transfer technologies. Its extensive portfolio of proprietary platforms includes UltraVector, which leverages advanced DNA construction and computational modeling to engineer complex gene expression programs; mbIL15, a gene designed to enhance immune cell function; the non-viral Sleeping Beauty transposon/transposase system f…
Open full interactive analysis & DCF →